Liposomes are a type of nano-sized phospholipid bubbles, which have attracted much attention as potential drug carriers. Liposomes are highly biocompatible and easy to control in vivo and can be loaded with a broad variety of drugs, DNA, and diagnostic agents. To date, a variety of liposomal drugs are under development and some of them are already approved for clinical use.
The global market for Liposome Development Service was estimated to be worth US$ 1020 million in 2023 and is forecast to a readjusted size of US$ 1807.1 million by 2030 with a CAGR of 8.1% during the forecast period 2024-2030
Global key players of liposome development service include Precision NanoSystems, Evonik, Merck KGaA, Genevant Sciences, Exelead, etc. The top two players hold a share over 52%. North America is the largest market, has a share about 61%, followed by Europe and Asia-Pacific, with share 26% and 11%, separately. In terms of product type, Lipid Nanoparticles is the largest segment, occupied for a share of 62%, and in terms of application, Commercial has a share about 86 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Liposome Development Service, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Liposome Development Service by region & country, by Type, and by Application.
The Liposome Development Service market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposome Development Service.
Market Segmentation
By Company
Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics
Creative Biolabs
Creative Biostructure
T&T Scientific
FormuMax Scientific
PlantaCorp
CD Bioparticles
Segment by Type:
Liposomes
Lipid Nanoparticles
Segment by Application
Preclinical
Clinical
Commercial
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Liposome Development Service manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Liposome Development Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Liposome Development Service in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Liposome Development Service Product Introduction
1.2 Global Liposome Development Service Market Size Forecast
1.3 Liposome Development Service Market Trends & Drivers
1.3.1 Liposome Development Service Industry Trends
1.3.2 Liposome Development Service Market Drivers & Opportunity
1.3.3 Liposome Development Service Market Challenges
1.3.4 Liposome Development Service Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Liposome Development Service Players Revenue Ranking (2023)
2.2 Global Liposome Development Service Revenue by Company (2019-2024)
2.3 Key Companies Liposome Development Service Manufacturing Base Distribution and Headquarters
2.4 Key Companies Liposome Development Service Product Offered
2.5 Key Companies Time to Begin Mass Production of Liposome Development Service
2.6 Liposome Development Service Market Competitive Analysis
2.6.1 Liposome Development Service Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Liposome Development Service Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposome Development Service as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Liposomes
3.1.2 Lipid Nanoparticles
3.2 Global Liposome Development Service Sales Value by Type
3.2.1 Global Liposome Development Service Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Liposome Development Service Sales Value, by Type (2019-2030)
3.2.3 Global Liposome Development Service Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Preclinical
4.1.2 Clinical
4.1.3 Commercial
4.2 Global Liposome Development Service Sales Value by Application
4.2.1 Global Liposome Development Service Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Liposome Development Service Sales Value, by Application (2019-2030)
4.2.3 Global Liposome Development Service Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Liposome Development Service Sales Value by Region
5.1.1 Global Liposome Development Service Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Liposome Development Service Sales Value by Region (2019-2024)
5.1.3 Global Liposome Development Service Sales Value by Region (2025-2030)
5.1.4 Global Liposome Development Service Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Liposome Development Service Sales Value, 2019-2030
5.2.2 North America Liposome Development Service Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Liposome Development Service Sales Value, 2019-2030
5.3.2 Europe Liposome Development Service Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Liposome Development Service Sales Value, 2019-2030
5.4.2 Asia Pacific Liposome Development Service Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Liposome Development Service Sales Value, 2019-2030
5.5.2 South America Liposome Development Service Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Liposome Development Service Sales Value, 2019-2030
5.6.2 Middle East & Africa Liposome Development Service Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Liposome Development Service Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Liposome Development Service Sales Value
6.3 United States
6.3.1 United States Liposome Development Service Sales Value, 2019-2030
6.3.2 United States Liposome Development Service Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Liposome Development Service Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Liposome Development Service Sales Value, 2019-2030
6.4.2 Europe Liposome Development Service Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Liposome Development Service Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Liposome Development Service Sales Value, 2019-2030
6.5.2 China Liposome Development Service Sales Value by Type (%), 2023 VS 2030
6.5.3 China Liposome Development Service Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Liposome Development Service Sales Value, 2019-2030
6.6.2 Japan Liposome Development Service Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Liposome Development Service Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Liposome Development Service Sales Value, 2019-2030
6.7.2 South Korea Liposome Development Service Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Liposome Development Service Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Liposome Development Service Sales Value, 2019-2030
6.8.2 Southeast Asia Liposome Development Service Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Liposome Development Service Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Liposome Development Service Sales Value, 2019-2030
6.9.2 India Liposome Development Service Sales Value by Type (%), 2023 VS 2030
6.9.3 India Liposome Development Service Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Precision NanoSystems
7.1.1 Precision NanoSystems Profile
7.1.2 Precision NanoSystems Main Business
7.1.3 Precision NanoSystems Liposome Development Service Products, Services and Solutions
7.1.4 Precision NanoSystems Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.1.5 Precision NanoSystems Recent Developments
7.2 Evonik
7.2.1 Evonik Profile
7.2.2 Evonik Main Business
7.2.3 Evonik Liposome Development Service Products, Services and Solutions
7.2.4 Evonik Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.2.5 Evonik Recent Developments
7.3 Merck KGaA
7.3.1 Merck KGaA Profile
7.3.2 Merck KGaA Main Business
7.3.3 Merck KGaA Liposome Development Service Products, Services and Solutions
7.3.4 Merck KGaA Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.3.5 Genevant Sciences Recent Developments
7.4 Genevant Sciences
7.4.1 Genevant Sciences Profile
7.4.2 Genevant Sciences Main Business
7.4.3 Genevant Sciences Liposome Development Service Products, Services and Solutions
7.4.4 Genevant Sciences Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.4.5 Genevant Sciences Recent Developments
7.5 Exelead
7.5.1 Exelead Profile
7.5.2 Exelead Main Business
7.5.3 Exelead Liposome Development Service Products, Services and Solutions
7.5.4 Exelead Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.5.5 Exelead Recent Developments
7.6 Avanti Polar Lipids
7.6.1 Avanti Polar Lipids Profile
7.6.2 Avanti Polar Lipids Main Business
7.6.3 Avanti Polar Lipids Liposome Development Service Products, Services and Solutions
7.6.4 Avanti Polar Lipids Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.6.5 Avanti Polar Lipids Recent Developments
7.7 Nippon Fine Chemical
7.7.1 Nippon Fine Chemical Profile
7.7.2 Nippon Fine Chemical Main Business
7.7.3 Nippon Fine Chemical Liposome Development Service Products, Services and Solutions
7.7.4 Nippon Fine Chemical Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.7.5 Nippon Fine Chemical Recent Developments
7.8 Lipoid
7.8.1 Lipoid Profile
7.8.2 Lipoid Main Business
7.8.3 Lipoid Liposome Development Service Products, Services and Solutions
7.8.4 Lipoid Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.8.5 Lipoid Recent Developments
7.9 Polymun Scientific
7.9.1 Polymun Scientific Profile
7.9.2 Polymun Scientific Main Business
7.9.3 Polymun Scientific Liposome Development Service Products, Services and Solutions
7.9.4 Polymun Scientific Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.9.5 Polymun Scientific Recent Developments
7.10 Corden Pharma
7.10.1 Corden Pharma Profile
7.10.2 Corden Pharma Main Business
7.10.3 Corden Pharma Liposome Development Service Products, Services and Solutions
7.10.4 Corden Pharma Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.10.5 Corden Pharma Recent Developments
7.11 Acuitas Therapeutics
7.11.1 Acuitas Therapeutics Profile
7.11.2 Acuitas Therapeutics Main Business
7.11.3 Acuitas Therapeutics Liposome Development Service Products, Services and Solutions
7.11.4 Acuitas Therapeutics Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.11.5 Acuitas Therapeutics Recent Developments
7.12 Creative Biolabs
7.12.1 Creative Biolabs Profile
7.12.2 Creative Biolabs Main Business
7.12.3 Creative Biolabs Liposome Development Service Products, Services and Solutions
7.12.4 Creative Biolabs Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.12.5 Creative Biolabs Recent Developments
7.13 Creative Biostructure
7.13.1 Creative Biostructure Profile
7.13.2 Creative Biostructure Main Business
7.13.3 Creative Biostructure Liposome Development Service Products, Services and Solutions
7.13.4 Creative Biostructure Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.13.5 Creative Biostructure Recent Developments
7.14 T&T Scientific
7.14.1 T&T Scientific Profile
7.14.2 T&T Scientific Main Business
7.14.3 T&T Scientific Liposome Development Service Products, Services and Solutions
7.14.4 T&T Scientific Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.14.5 T&T Scientific Recent Developments
7.15 FormuMax Scientific
7.15.1 FormuMax Scientific Profile
7.15.2 FormuMax Scientific Main Business
7.15.3 FormuMax Scientific Liposome Development Service Products, Services and Solutions
7.15.4 FormuMax Scientific Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.15.5 FormuMax Scientific Recent Developments
7.16 PlantaCorp
7.16.1 PlantaCorp Profile
7.16.2 PlantaCorp Main Business
7.16.3 PlantaCorp Liposome Development Service Products, Services and Solutions
7.16.4 PlantaCorp Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.16.5 PlantaCorp Recent Developments
7.17 CD Bioparticles
7.17.1 CD Bioparticles Profile
7.17.2 CD Bioparticles Main Business
7.17.3 CD Bioparticles Liposome Development Service Products, Services and Solutions
7.17.4 CD Bioparticles Liposome Development Service Revenue (US$ Million) & (2019-2024)
7.17.5 CD Bioparticles Recent Developments
8 Industry Chain Analysis
8.1 Liposome Development Service Industrial Chain
8.2 Liposome Development Service Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Liposome Development Service Sales Model
8.5.2 Sales Channel
8.5.3 Liposome Development Service Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics
Creative Biolabs
Creative Biostructure
T&T Scientific
FormuMax Scientific
PlantaCorp
CD Bioparticles
*If Applicable.